dc.contributor.author | STEVENSON, NIGEL | |
dc.date.accessioned | 2019-08-12T15:33:13Z | |
dc.date.available | 2019-08-12T15:33:13Z | |
dc.date.issued | 2016-03-24 | |
dc.date.submitted | 2016 | en |
dc.identifier.citation | Mahony R, Ahmed S, Diskin C, Stevenson NJ, SOCS3 revisited: a broad regulator of disease, ready for therapeutic use?, Cellular and Molecular Life Sciences, 73, 17, 2016, 3323 - 3336 | en |
dc.identifier.other | Y | |
dc.identifier.uri | doi: 10.1007/s00018-016-2234-x | |
dc.identifier.uri | http://hdl.handle.net/2262/89173 | |
dc.description | PUBLISHED | en |
dc.description.abstract | Since their discovery, SOCS have been characterised
as regulatory cornerstones of intracellular
signalling. While classically controlling the JAK/STAT
pathway, their inhibitory effects are documented across
several cascades, underpinning their essential role in
homeostatic maintenance and disease. After 20 years of
extensive research, SOCS3 has emerged as arguably the
most important family member, through its regulation of
both cytokine- and pathogen-induced cascades. In fact, low
expression of SOCS3 is associated with autoimmunity and
oncogenesis, while high expression is linked to diabetes
and pathogenic immune evasion. The induction of SOCS3
by both viruses and bacteria and its impact upon inflammatory
disorders, underscores this protein’s increasing
clinical potential. Therefore, with the aim of highlighting
SOCS3 as a therapeutic target for future development, this
review revisits its multi-faceted immune regulatory functions
and summarises its role in a broad ranges of diseases. | en |
dc.format.extent | 3323 | en |
dc.format.extent | 3336 | en |
dc.language.iso | en | en |
dc.publisher | Springer | en |
dc.relation.ispartofseries | Cellular and Molecular Life Sciences; | |
dc.relation.ispartofseries | 73; | |
dc.relation.ispartofseries | 17; | |
dc.rights | Y | en |
dc.subject | Rheumatoid arthritis | en |
dc.subject | Cancer | en |
dc.subject | Diabetes | en |
dc.subject | Infection | en |
dc.subject | Suppressor of cytokine signalling (SOCS) | en |
dc.subject | Janus kinase/signal transduction and activator of transcription (JAK/STAT) | en |
dc.title | SOCS3 revisited: a broad regulator of disease, ready for therapeutic use? | en |
dc.type | Journal Article | en |
dc.contributor.sponsor | Health Research Board (HRB) | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/stevennj | |
dc.identifier.rssinternalid | 136218 | |
dc.rights.ecaccessrights | embargoedAccess | |
dc.date.ecembargoEndDate | 2066-03-24 | |
dc.subject.TCDTheme | Immunology, Inflammation & Infection | en |
dc.identifier.orcid_id | 0000-0002-6966-9314 | |
dc.status.accessible | N | en |